Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Latest news articles

Added 6 months ago Drug news

FDA's clinical hold on all trials of SB 1518 (pacritinib) for patients with myelofibrosis now removed- CTI BioPharma

CTI BioPharma announced that the full clinical hold (February 2016) implemented by the FDA on all clinical trials conducted under...

Added 8 months ago Drug news

Results from Phase III studies SIMPLIFY-1 and SIMPLIFY-2 for momelotinib to treat myelofibrosis.- Gilead Sciences

Gilead Sciences, Inc. announced top-line results from two Phase III clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational...

Added 10 months ago Drug news

Phase III clinical trial of SB 1518 (pacritinib) meets one co-endpoint in myelofibrosis - CTI BioPharma

CTI BioPharma Corp has announced top-line results from PERSIST-2, a randomized, controlled Phase III clinical trial comparing SB 1518 (pacritinib),...

Search all news articles for Other haematologic conditions
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)


Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation


Guidelines

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...

Added 2 years ago

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

The British Committee for Standards in Haematology (BCSH) Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012), but...

Added 2 years ago

Guideline for the diagnosis and management of myelofibrosis

The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary...

Added 4 years ago

Search all guidelines for Other haematologic conditions
 

Journal articles

Erythrocytosis following testosterone therapy.

A rapid increase in awareness of androgen deficiency has led to substantial increases in prescribing of testosterone therapy (TTh), with benefits of improvements in mood, libido, bone density, muscle mass, body composition, energy, and cognition.

Added 23 days ago

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World Health Organization Classification of Tumors and Haematopoietic and Lymphoid Tissue.

Added 1 month ago

Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

IMPORTANCE: Gaucher disease type 1 is characterized by hepatosplenomegaly, anemia, thrombocytopenia, and skeletal disease. A safe, effective oral therapy is...

Added 2 years ago

Search all journal articles for Other haematologic conditions